BioSpace News Archive

Tell us more about yourself so we can deliver a better experience on BioSpace. Your data isn’t shared.

Download recent case study highlighting the power of employer branding aligned with a strategic BioSpace partnership.

Josh joined Evotec’s Business Development team in 2019, bringing nearly 20 years of experience as a drug developer in the Boston/Cambridge biotechnology hub.

Prior to Evotec, he held leadership roles at Idenix Pharmaceuticals, Dimension Therapeutics, and Navitor Pharmaceuticals. In these positions, he was a long-standing client of Evotec and its subsidiary Aptuit, successfully leading five IND-enabling development programs utilizing Evotec’s integrated platform.

Since joining Evotec, Josh has leveraged his deep drug development expertise to enhance client relationships and align Evotec’s offerings with partner expectations.

He currently serves as Vice President of Business Development, supporting partners in New York, Connecticut, Massachusetts, and Eastern Canada.

Marina has 25 years of experience in pharmaceutical development, supporting the progression of new chemical entities from candidate selection through clinical phases.

She began her career as a Scientist at GlaxoSmithKline, gaining a strong foundation in drug substance and drug product analytics, including pre-formulation, degradation chemistry, and stability studies. As a CMC Leader at Aptuit and later a Scientific Project Leader at Evotec, she oversaw more than 40 integrated development programs.

In her current role as Vice President of Scientific Strategy, Marina serves as a senior development expert, supporting business development efforts and the design of customized integrated development plans for partners. She also contributes to the continuous evolution of Evotec’s integrated service offerings.

Shankar Sankaran leads a team of more than 50 chemists as executive director of analytical for SK Pharmteco, a global contract development and manufacturing organization based in Rancho Cordova, California. SK Pharmteco’s analytical business unit provides testing and validation for its in-house pharma manufacturing as well as external contracts with third parties.

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock tumbling in pre-market trading.

iTeos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 full-time employees at the end of 2024.

Whether you’re moving on or being moved out, how you leave can shape your reputation more than how you led.

Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.